|Bid||10.59 x 800|
|Ask||10.70 x 1000|
|Day's range||10.41 - 10.69|
|52-week range||7.13 - 15.24|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||N/A|
|Earnings date||07 Feb 2023 - 13 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.80|
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.